SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Korro Bio, Inc. (KRRO) News

Follow Korro Bio, Inc. (KRRO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol KRRO Asset equity Sector Markets 90 days 7 Last 12.245 Updated Nov 05, 2026, 08:02 PM UTC Open live news feed Open KRRO chart & news
M Korro Bio Shares Fall 11% After Novo Nordisk Ends Collaboration Korro Bio said Novo Nordisk terminated a research collaboration and license agreement. Korro Bio shares fell 11% to $14.88 midday Thursday, after rising about 86% year to date. EQUITY | Nov 05, 2026, 08:02 PM UTC M Korro Bio Reports Zero Revenue and $0.98 Loss in Third Quarter Korro Bio reported no collaboration revenue in the third quarter, down from $1.1 million a year earlier, while its net loss narrowed. Lower research and development costs, primarily following termination of the KRRO-110 EARNINGS | Nov 05, 2026, 12:14 PM UTC M Korro Bio Reports Third-Quarter Loss per Share EQUITY | Nov 05, 2026, 12:06 PM UTC L Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) NASDAQ:KRRO, a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of NEWS | Sep 11, 2026, 08:11 PM UTC L KRRO - Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) KRRO - Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NEWS | Sep 11, 2026, 08:05 PM UTC L Korro to Participate in Upcoming Investor Conferences Korro to Participate in Upcoming Investor Conferences EQUITY | Aug 27, 2026, 11:07 AM UTC L KRRO - Korro to Participate in Upcoming Investor Conferences KRRO - Korro to Participate in Upcoming Investor Conferences EQUITY | Aug 27, 2026, 11:00 AM UTC L Korro Bio reports inducement grant under Nasdaq Rule 5635(c)(4) Korro Bio reports an inducement grant under Nasdaq Listing Rule 5635(c)(4); no grant size, recipient details or catalyst was supplied. REGULATION | Aug 14, 2026, 08:05 PM UTC L Korro Bio Form 4: Lynx1 Capital Management LPP buys 6,684 shares Korro Bio, Inc. files a Form 4 showing 10% owner Lynx1 Capital Management LPP purchasing 6,684 shares at $11.791 per share for a reported $78,809 total. REGULATION | Aug 13, 2026, 02:06 PM UTC L KRRO - Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update KRRO - Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update EARNINGS | Aug 06, 2026, 11:01 AM UTC L Korro Bio Insider Sold Shares Worth $1,542,970, According to a Recent SEC Filing () -- Jean Francois Formela, Director, on July 02, 2026, sold 110,023 shares in Korro Bio (KRRO) for $1,542,970. Following the Form 4 filing with the SEC, Formela has control over a total of 852,861 common shares of the REGULATION | Jul 08, 2026, 08:06 AM UTC